Abstract
As the COVID 19 pandemic evolves, concerns about fungal co-infections and superinfections are increasing, mainly towards invasive pulmonary aspergillosis (IPA), which increases significantly the risk of mortality in these patients, thus requiring early detection and diagnosis for better treatment efficiency. We’re describing the case of a young, non-immunocompromised patient with SARS COV 2 infection, who developed an IPA due to Aspergillus flavus.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
